HM Payson & Co. Buys 97,715 Shares of Quotient Limited (NASDAQ:QTNT)

HM Payson & Co. boosted its stake in Quotient Limited (NASDAQ:QTNT) by 19,543.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,215 shares of the company’s stock after purchasing an additional 97,715 shares during the quarter. HM Payson & Co. owned about 0.10% of Quotient worth $512,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Polar Capital LLP increased its holdings in Quotient by 21.9% in the third quarter. Polar Capital LLP now owns 9,251,653 shares of the company’s stock valued at $47,553,000 after purchasing an additional 1,660,588 shares during the last quarter. Credit Suisse AG grew its stake in Quotient by 2.1% in the fourth quarter. Credit Suisse AG now owns 5,959,351 shares of the company’s stock valued at $31,048,000 after acquiring an additional 124,078 shares during the period. BlackRock Inc. grew its stake in Quotient by 31.6% in the fourth quarter. BlackRock Inc. now owns 5,069,361 shares of the company’s stock valued at $26,411,000 after acquiring an additional 1,217,469 shares during the period. Clearbridge Investments LLC grew its stake in Quotient by 2.5% in the fourth quarter. Clearbridge Investments LLC now owns 4,187,830 shares of the company’s stock valued at $21,819,000 after acquiring an additional 102,235 shares during the period. Finally, Artisan Partners Limited Partnership grew its stake in Quotient by 21.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,263,609 shares of the company’s stock valued at $17,003,000 after acquiring an additional 567,887 shares during the period. Institutional investors and hedge funds own 80.81% of the company’s stock.

In other news, insider Jeremy Stackawitz sold 30,000 shares of the company’s stock in a transaction dated Thursday, February 4th. The stock was sold at an average price of $5.14, for a total transaction of $154,200.00. Following the completion of the transaction, the insider now directly owns 112,926 shares of the company’s stock, valued at $580,439.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 12.30% of the stock is owned by corporate insiders.

NASDAQ:QTNT opened at $3.86 on Thursday. Quotient Limited has a 1 year low of $3.43 and a 1 year high of $10.38. The company has a current ratio of 4.50, a quick ratio of 3.98 and a debt-to-equity ratio of 4.34. The stock has a market cap of $390.37 million, a price-to-earnings ratio of -3.27 and a beta of 2.60. The stock has a 50-day moving average price of $4.26 and a two-hundred day moving average price of $5.36.

Quotient (NASDAQ:QTNT) last posted its earnings results on Sunday, January 31st. The company reported ($0.29) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.29). The firm had revenue of $8.75 million during the quarter, compared to analysts’ expectations of $8.40 million. Quotient had a negative return on equity of 2,307.27% and a negative net margin of 222.46%. Sell-side analysts forecast that Quotient Limited will post -1 earnings per share for the current year.

Separately, Zacks Investment Research raised Quotient from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Friday, December 11th.

Quotient Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening.

See Also: Cryptocurrencies

Institutional Ownership by Quarter for Quotient (NASDAQ:QTNT)

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with's FREE daily email newsletter.